Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRO-K 10 vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitals or diuretics for congestive heart failure, hepatic cirrhosis, or nephrotic syndrome,Correction of hypokalemia in patients with hypertension on long-term diuretic therapy
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Not applicable; potassium is not cleared by first-order kinetics. Whole-body potassium turnover half-life is approximately 30 days, but this is not clinically relevant for supplementation.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium is not metabolized. Approximately 90% of ingested potassium is excreted in the urine, with the remainder excreted in feces and sweat. There is no hepatic metabolism.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Primarily renal: 90% of absorbed potassium is excreted in urine as potassium ions; 10% eliminated in feces via biliary and intestinal secretion.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
0% bound to serum proteins; free ion in serum.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
Total body water: 0.5 L/kg; distributes primarily intracellularly (98% of body potassium is intracellular), but Vd is not a clinically relevant parameter for potassium.
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Oral (microencapsulated): 90-100% relative to intravenous; absorption is nearly complete via the gastrointestinal tract.
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50% or use with caution. GFR <10 m L/min: contraindicated or use with extreme caution.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to risk of hyperkalemia.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
Children: 1-2 m Eq/kg/day in divided doses, not to exceed 20 m Eq per dose or 100 m Eq/day. Minimum dosing weight not specified; safety and efficacy not established in premature infants.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Elderly: start with lower doses (e.g., 10 m Eq once daily) due to age-related renal function decline; monitor serum potassium and renal function frequently.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
None
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Hyperkalemia risk; use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Gastrointestinal irritation and ulceration; do not crush or chew tablets,May increase serum potassium levels in patients with adrenal insufficiency or diabetes,Use caution with potassium-sparing diuretics or ACE inhibitors
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Severe renal impairment with oliguria or azotemia,Addison's disease,Acute dehydration,Heat cramps,Hyperkalemia from any cause,Concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, salt substitutes) unless directed otherwise; intake may need to be restricted or monitored.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or adverse outcomes. Recommended intakes are safe.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium is a normal constituent of breast milk with an M/P ratio of approximately 0.1-0.2. Supplemental potassium is not expected to cause adverse effects in nursing infants at usual maternal doses.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No specific dose adjustment required for pregnancy. However, increased plasma volume and renal blood flow during pregnancy may lower serum potassium, potentially requiring higher doses for hypokalemia treatment. Individualize based on serum potassium monitoring.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Micro-K 10 (potassium chloride extended-release) is used for hypokalemia. Avoid in severe renal impairment (Cr Cl <30 m L/min) due to risk of hyperkalemia. Do not crush or chew capsules; administer with food to reduce GI irritation. Monitoring serum potassium levels is essential, especially in patients on digoxin or diuretics. Use with caution in patients with significant heart block or metabolic acidosis.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
Take this medication exactly as prescribed, usually once daily with food.,Do not crush, chew, or open the capsule; swallow whole.,Do not use salt substitutes or potassium supplements unless instructed by your doctor.,Seek medical attention if you experience muscle weakness, irregular heartbeat, or signs of GI obstruction (severe stomach pain, vomiting, or black stools).,Tell your doctor about all medications, especially diuretics or ACE inhibitors.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRO-K 10 vs KAON CL, answered by our medical review team.
MICRO-K 10 is a Electrolyte Supplement (Potassium) that works by Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRO-K 10 and KAON CL depend on the specific clinical indication. These are both Electrolyte Supplement (Potassium) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRO-K 10 is: 10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRO-K 10 and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRO-K 10 is classified as Category C. Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.